Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders - Vertex Pharmaceutic

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at…

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions